Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected Subjects
Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety and efficacy of a combination of a QD
regimen consisting on ritonavir boosted darunavir (FDC) and lamivudine versus ritonavir
boosted darunavir (FDC) plus co-formulated tenofovir and emtricitabine or co-formulated
tenofovir/lamivudine in naïve HIV-1 infected patients. Subjects will be ARV-naïve
HIV-1-infected patients eligible to start ARV therapy according to current
guidelines.Subjects will be adults ≥ 18 years of age who meet all of the inclusion criteria
and none of the exclusion criteria.
Phase:
Phase 4
Details
Lead Sponsor:
Fundación Huésped The Huesped Foundation
Collaborators:
Ministry of Science and Technology,Argentine National AIDS and STD programme,Argentine Richmond Laboratories